Matinas $MTNB Study Versus Amarin $AMRN

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

Here is the Matinas CEO in an interview post Vascepa label expansion, saying everything that JT meant to say on CNBC but couldn't articulate properly.


There are so many AMRN investors who wish that guy was their CEO. Stock would be at $30 by now. Ha.

post

Matinas' lead product candidate is MAT9001 and is different than Vascepa but still focused on the treatment of cardiovascular and metabolic conditions.

Matinas describes MAT9001 as a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class.

Most people do believe that any success that Amarin has will lift Matinus up and eventually lead to a buyout before they ever get to market.

Here is the Matinas CEO in an interview post Vascepa label expansion, saying everything that JT meant to say on CNBC but couldn't articulate properly.


post

In listening to the Jerome's Piper Jaffray conference presentation, he led off with the success of Vascepa and made the comment of "rising tides" when discussing Matinus' portfolio. He also talked about the expanded label for Vascepa and said he expects the FDA to give Amarin a wide label. Good things for both companies and I do think MTNB will rise along with AMRN.

Matinas' lead product candidate is MAT9001 and is different than Vascepa but still focused on the treatment of cardiovascular and metabolic conditions.

Matinas describes MAT9001 as a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class.

Most people do believe that any success that Amarin has will lift Matinus up and eventually lead to a buyout before they ever get to market.

post

In listening to the Jerome's Piper Jaffray conference presentation, he led off with the success of Vascepa and made the comment of "rising tides" when discussing Matinas' portfolio. He also talked about the expanded label for Vascepa and said he expects the FDA to give Amarin a wide label. Good things for both companies and I do think MTNB will rise along with AMRN.

post

$MTNB Phase II pharmacodynamic study completion Nov 2020, Phase III to be announced eventually. $AMRN wannabe with a long road ahead. pic.twitter.com/fBufw8s35w

A wannabe Amarin???

post

Loading...


Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.